April 28, 2026
1 min watch
COPENHAGEN, Denmark — In this Healio video, Alissa J. Cooper, MD, a thoracic oncologist at Dana-Farber Cancer Institute, discusses results from the phase 3 PRESERVE-003 trial, which were presented at European Lung Cancer Congress.
The randomized trial compared gotistobart (BNT316/ONC-392; BioNTech, OncoC4), a novel anti-CTLA-4 antibody, with docetaxel among patients with metastatic squamous non-small cell lung cancer who had progressed on immunotherapy and chemotherapy.
“This was very positive,” said Cooper, noting better objective response rate and 12-month PFS and OS in the gotistobart arm.
Sources/Disclosures
Source:
Healio Interviews
Reference:
- Cho BC, et al. Abstract 30. Presented at: European Lung Cancer Congress; March 25-28, 2026; Copenhagen, Denmark.
Disclosures:
Cooper reports honoraria from CancerGRACE, IDEOlogy Health, Intellisphere, MedStar Health, MJH Life Sciences and PeerDirect; consulting roles with AbbVie, Amgen, Boehringer Ingelheim, Daiichi Sankyo/AstraZeneca, Gilead Sciences, Novartis and Regeneron; and prior institutional research funding from AbbVie, Amgen, Daiichi Sankyo, Merck, Monte Rosa Therapeutics and Roche.
Ask a clinical question and tap into Healio AI’s knowledge base.
- PubMed, enrolling/recruiting trials, guidelines
- Clinical Guidance, Healio CME, FDA news
- Healio’s exclusive daily news coverage of clinical data
<
Leave a Reply